Recurrent Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage I Prostate Cancer
Conditions
Brief summary
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with prostate cancer after undergoing surgery. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
Detailed description
PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) with an upper limit of 45 Gray (Gy) in 5 fractions, in the delivery of stereotactic body radiation therapy (SBRT) to the prostate fossa. SECONDARY OBJECTIVES: I. To assess acute and late toxicities from treatment. II. To assess biochemical progression-free survival. III. To collect prospective quality-of-life data related to bowel, urinary, and sexual health. OUTLINE: This is a dose-escalation study. Patients receive 5 fractions of SBRT over 1.5 weeks. After completion of study treatment, patients are followed up at 90 days and then periodically for 3 years.
Interventions
RADIATIONstereotactic body radiation therapy
Undergo SBRT
PROCEDUREquality-of-life assessment
Ancillary studies
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
City of Hope Medical Center
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* History of diagnosis of prostate cancer after undergoing prostatectomy * No evidence of regional nodal or distant metastases based on computed tomography (CT) abdomen and pelvis and whole body bone scan within 120 days prior to study entry; nodes less than 1.5 cm will be considered reactive and biopsy is not required; nodes 1.5 cm or larger are required to undergo biopsy and be negative prior to study registration; bone scan findings in the absence of blastic or lytic lesion correlates on CT imaging will also be deemed non-neoplastic * Eastern Cooperative Oncology Group (ECOG) performance scale 0-2 * Child bearing potential: In this patient population, this pertains to the ability to conceive a child; eligible patients already have received prostatectomy, and therefore this risk is not applicable * Prostate specific antigen (PSA) value can be undetectable up to a value of 2.0 within 30 days prior to study entry * PSA value that is undetectable can be enrolled if pathology from prostatectomy demonstrates one or more of the following: positive margin, extracapsular extension, or seminal vesicle invasion * All subjects must have the ability to understand and the willingness to sign a written informed consent
Exclusion criteria
* Patients should not have any uncontrolled illness including ongoing or active infection * Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy * Patients with history of prior malignancies (with exception to non-melanoma skin cancer) are ineligible for this study, unless they are documented to be disease-free for at least 5 years * Study-specific exclusions: * History of prior radiation to the pelvis * History of uncontrolled inflammatory bowel disease * Unable to comply with radiation therapy procedures * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MTD, defined as the highest dose tested in which fewer than 33% of patients experienced dose limiting toxicity, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 | 90 days | Tables will be created to summarize these toxicities and side effects by dose level. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of acute toxicities observed at each dose level graded according to the NCI CTCAE version 4.0 | Up to 90 days | Tables will be created to summarize these toxicities and side effects by dose level. |
| Incidence of late toxicities observed at each dose level graded according to the NCI CTCAE version 4.0 | Up to 3 years | Tables will be created to summarize these toxicities and side effects by dose level. |
| Biochemical progression-free survival | Up to 3 years | Estimated using Kaplan-Meier. 95% confidence intervals should be provided. |
| Prospective quality-of-life data related to bowel, urinary, and sexual health using the numerical scores generated from the patient questionnaires | Up to 3 years | Quality of life questionnaires include the International Prostate Symptom Scale (IPSS), sexual health inventory for men (SHIM), and Merrick rectal function scale. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSagus Sampath
City of Hope Medical Center
Outcome results
None listed